First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment o...
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial
About this item
Full title
Author / Creator
Joly, Pascal, Professor , Maho-Vaillant, Maud, PhD , Prost-Squarcioni, Catherine, Prof , Hebert, Vivien, MD , Houivet, Estelle, MS , Calbo, Sébastien, PhD , Caillot, Frédérique, PhD , Golinski, Marie Laure, PhD , Labeille, Bruno, Prof , Picard-Dahan, Catherine, MD , Paul, Carle, Prof , Richard, Marie-Aleth, Prof , Bouaziz, Jean David, Prof , Duvert-Lehembre, Sophie, MD , Bernard, Philippe, Prof , Caux, Frederic, Prof , Alexandre, Marina, MD , Ingen-Housz-Oro, Saskia, MD , Vabres, Pierre, Prof , Delaporte, Emmanuel, Prof , Quereux, Gaelle, Prof , Dupuy, Alain, Prof , Debarbieux, Sebastien, MD , Avenel-Audran, Martine, MD , D'Incan, Michel, Prof , Bedane, Christophe, Prof , Bénéton, Nathalie, MD , Jullien, Denis, Prof , Dupin, Nicolas, Prof , Misery, Laurent, Prof , Machet, Laurent, Prof , Beylot-Barry, Marie, Prof , Dereure, Olivier, Prof , Sassolas, Bruno, MD , Vermeulin, Thomas, MD , Benichou, Jacques, Prof , Musette, Philippe, Prof and French study group on autoimmune bullous skin diseases
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background High doses of corticosteroids are considered the standard treatment for pemphigus. Because long-term corticosteroid treatment can cause severe and even life-threatening side-effects in patients with this disease, we assessed whether first-line use of rituximab as adjuvant therapy could improve the proportion of patients achieving...
Alternative Titles
Full title
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial
Authors, Artists and Contributors
Author / Creator
Maho-Vaillant, Maud, PhD
Prost-Squarcioni, Catherine, Prof
Hebert, Vivien, MD
Houivet, Estelle, MS
Calbo, Sébastien, PhD
Caillot, Frédérique, PhD
Golinski, Marie Laure, PhD
Labeille, Bruno, Prof
Picard-Dahan, Catherine, MD
Paul, Carle, Prof
Richard, Marie-Aleth, Prof
Bouaziz, Jean David, Prof
Duvert-Lehembre, Sophie, MD
Bernard, Philippe, Prof
Caux, Frederic, Prof
Alexandre, Marina, MD
Ingen-Housz-Oro, Saskia, MD
Vabres, Pierre, Prof
Delaporte, Emmanuel, Prof
Quereux, Gaelle, Prof
Dupuy, Alain, Prof
Debarbieux, Sebastien, MD
Avenel-Audran, Martine, MD
D'Incan, Michel, Prof
Bedane, Christophe, Prof
Bénéton, Nathalie, MD
Jullien, Denis, Prof
Dupin, Nicolas, Prof
Misery, Laurent, Prof
Machet, Laurent, Prof
Beylot-Barry, Marie, Prof
Dereure, Olivier, Prof
Sassolas, Bruno, MD
Vermeulin, Thomas, MD
Benichou, Jacques, Prof
Musette, Philippe, Prof
French study group on autoimmune bullous skin diseases
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_hal_primary_oai_HAL_hal_01540071v1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_01540071v1
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(17)30070-3
